Q BioMed Acquires Rights of Metastron from GE Healthcare
Shots:
• GE Healthcare to receive upfront- milestone and single digit royalties for 15 yrs and Q BioMed to get rights of Metastron- in 22 approved countries
• The acquisition of Metastron will support as a non-opioid therapy to treat debilitating pain associated with skeletal cancer metastases and is expected to expand the scope of drug
• Metastron (Strontium Chloride- Sr-89) IV is a non-narcotic analgesic- indicated for reduction of bone pain palliation in metastatic cancer
Ref: Q BioMed | Image: HIT Consultant
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com